HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Abstract Text:

Marijke Niens,Ruth F Jarrett,Bouke Hepkema,Ilja M Nolte,Arjan Diepstra,Mathieu Platteel,Niels Kouprie,Craig P Delury,Alice Gallagher,Lydia Visser,Sibrand Poppema,Gerard J te Meerman,Anke van den Berg,Marijke Niens,Ruth F Jarrett,Bouke Hepkema,Ilja M Nolte,Arjan Diepstra,Mathieu Platteel,Niels Kouprie,Craig P Delury,Alice Gallagher,Lydia Visser,Sibrand Poppema,Gerard J te Meerman,Anke van den Berg,

Previous studies showed that the HLA class I region is associated with Epstein-Barr virus (EBV)-positive Hodgkin lymphoma (HL) and that HLA-A is the most likely candidate gene in this region. This suggests that antigenic presentation of EBV-derived peptides in the context of HLA-A is involved in the pathogenesis of EBV+ HL by precluding efficient immune responses. We genotyped exons 2 and 3, encoding the peptide-binding groove of HLA-A, for 32 single nucleotide polymorphisms in 70 patients with EBV+ HL, 31 patients with EBV- HL, and 59 control participants. HLA-A*01 was significantly overrepresented and HLA-A*02 was significantly underrepresented in patients with EBV+ HL versus controls and patients with EBV- HL. In addition, HLA-A*02 status was determined by immunohistochemistry or HLA-A*02-specific polymerase chain reaction (PCR) on 152 patients with EBV+ HL and 322 patients with EBV- HL. The percentage of HLA-A*02+ patients in the EBV+ HL group (35.5%) was significantly lower than in 6107 general control participants (53.0%) and the EBV- HL group (50.9%). Our results indicate that individuals carrying the HLA-A*02 allele have a reduced risk of developing EBV+ HL, while individuals carrying the HLA-A*01 allele have an increased risk. It is known that HLA-A*02 can present EBV-derived peptides and can evoke an effective immune response, which may explain the protective phenotype.

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Publishing Authors By Initials

M Niens,RF Jarrett,B Hepkema,IM Nolte,A Diepstra,M Platteel,N Kouprie,CP Delury,A Gallagher,L Visser,S Poppema,GJ te Meerman,A van den Berg,M Niens,RF Jarrett,B Hepkema,IM Nolte,A Diepstra,M Platteel,N Kouprie,CP Delury,A Gallagher,L Visser,S Poppema,GJ te Meerman,A van den Berg,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Blood

VOLUME: 110

Page Numbers: 3310-5

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 13

MONTH: 07

YEAR: 2007

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.

AFFILIATION: Department of Genetics, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, the Netherlands.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma Related Publications

• Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis and content.
• Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options.
• Collision judgment of objects approaching the head.
• Communication between the corpus cavernosum penis and the corpus spongiosum penis in a bull diagnosed by modified contrast cavernosography: A case report.
• Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation.
• Delayed intrauterine repair of an experimental spina bifida with a collagen biomatrix.
• Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation.
• Energy conversion in microsystems: is there a role for micro/nanofluidics?
• Flash suppression and flash facilitation in binocular rivalry.
• Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device.
• HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.
• High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics.
• ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study.
• Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis.
• Lifetime occupation, education, smoking, and risk of ALS.
• Media exposure, mood, and body image dissatisfaction: an experimental test of person versus product priming.
• Multiphase flow in microfluidic systems --control and applications of droplets and interfaces.
• Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study.
• Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage.
• Pivotal role of ChIFNgamma in the pathogenesis and immunosuppression of infectious bursal disease.
• RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia.
• Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
• Redox cycling with facing interdigitated array electrodes as a method for selective detection of redox species.
• Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis.
• Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage.
• Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
• Shared risk and protective factors for overweight and disordered eating in adolescents.
• Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints.
• Structural insight into OprD substrate specificity.
• Vascular events after liver transplantation: a long-term follow-up study.